There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ...
Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts Tumors with ...
Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) Dosage and Drug Price Insight on Approved FGFR Inhibitors During the past few years, the demand of receptor ...
Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, ...
A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...
The median duration of response on erdafitinib among patients with FGFR fusions or mutations in the NCI-MATCH was <6 months. This may in part be due to low dependency on FGFR signaling in the genetic ...
Panel A shows the marked decreases in FGF23 levels (black curve) induced by infigratinib (gray bars indicate doses of the drug), which reversed when the patient was not receiving the drug. The timing ...
Hosted on MSN
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal ...
The first genetic mechanisms conferring acquired resistance to a promising group of targeted cancer drugs have now been identified by researchers. Investigators at the Massachusetts General Hospital ...
A mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors has now been uncovered by investigators. The researchers also found ...
N-cadherin and HER2/neu were found to be co-expressed in invasive breast carcinomas. To test the contribution of N-cadherin and HER2 in mammary tumor metastasis, we targeted N-cadherin expression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results